Roger Nitsch

Roger Nitsch

Director/Board Member en LONZA GROUP AG .

Fortuna: 221 310 $ al 31/03/2024

63 años
Health Technology
Commercial Services
Consumer Services

Perfil

Roger Nitsch is the founder of Evotec International GmbH (founded in 1995), Neurimmune AG (founded in 2006), and NovaGo Therapeutics AG (founded in 2015).
At Evotec International GmbH, he held the title of Director from 1995 to 1998.
At Neurimmune AG, he holds the titles of President, Chief Executive Officer & Director.
At NovaGo Therapeutics AG, he holds the title of Director.
Currently, Dr. Nitsch holds multiple jobs, including Chairman at Neurimmune Holding AG, Independent Director at Lonza Group AG (since 2022), Director at INTEGRA Biosciences AG (since 2002), Director at AL-S Pharma AG, Professor at the Institute For Regenerative Medicine (since 1998), and Professor at the University of Zurich (since 2018).

Participaciones conocidas en empresas públicas

EmpresaFechaNúmero de accionesValoraciónFecha de valoración
31/12/2023 369 ( 0.00% ) 221 310 $ 31/03/2024

Cargos activos de Roger Nitsch

EmpresasCargoInicio
LONZA GROUP AG Director/Board Member 01/05/2022
Director/Board Member -
Founder 01/01/2015
Neurimmune AG Founder 01/01/2006
Chairman -
Director/Board Member 01/01/2002
University of Zurich Corporate Officer/Principal 01/01/2018
Corporate Officer/Principal 01/01/1998
Todos los cargos activos de Roger Nitsch

Antiguos cargos conocidos de Roger Nitsch.

EmpresasCargoFin
Founder 01/01/1998
Ver el detalle de la experiencia de Roger Nitsch.

Experiencias
Funciones ocupadas

Activas

Inactivas

Empresas cotizadas

Empresas privadas

Ver el detalle de la experiencia de Roger Nitsch.

Relaciones

59

Relaciones de 1er grado

9

Empresas vinculadas al 1er grado

Hombre

Mujer

Administradores

Ejecutivos

Consultar la red personal

Empresas relacionadas

Empresas cotizadas1
LONZA GROUP AG

Health Technology

Empresas privadas7

Commercial Services

Commercial Services

Health Technology

Health Technology

Health Technology

Health Technology

Neurimmune AG

Ver las conexiones de la empresa